Cytosorbents (NASDAQ:CTSO) Share Price Crosses Above 200-Day Moving Average – What’s Next?

Cytosorbents Corporation (NASDAQ:CTSO) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.01 and traded as high as $1.37. Cytosorbents shares last traded at $1.26, with a volume of 210,583 shares changing hands.

Analyst Upgrades and Downgrades

A number of research firms have commented on CTSO. Wall Street Zen began coverage on shares of Cytosorbents in a research report on Wednesday, May 21st. They set a “hold” rating on the stock. D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a research report on Thursday, May 15th. Finally, HC Wainwright reissued a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a research report on Thursday, May 15th.

Cytosorbents Stock Performance

The business’s 50-day moving average price is $0.99 and its 200-day moving average price is $1.01. The company has a current ratio of 2.61, a quick ratio of 2.30 and a debt-to-equity ratio of 0.98. The stock has a market cap of $78.89 million, a PE ratio of -4.50 and a beta of 1.05.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings data on Wednesday, May 14th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. Cytosorbents had a negative net margin of 41.77% and a negative return on equity of 105.04%. The firm had revenue of $8.73 million for the quarter, compared to the consensus estimate of $9.01 million. As a group, equities research analysts expect that Cytosorbents Corporation will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of Cytosorbents

Several large investors have recently bought and sold shares of CTSO. Millennium Management LLC purchased a new stake in Cytosorbents during the 4th quarter worth approximately $30,000. Goldman Sachs Group Inc. grew its position in Cytosorbents by 149.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after purchasing an additional 37,519 shares during the last quarter. Key Client Fiduciary Advisors LLC grew its position in Cytosorbents by 127.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company’s stock worth $78,000 after purchasing an additional 43,900 shares during the last quarter. Renaissance Technologies LLC grew its position in Cytosorbents by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after purchasing an additional 8,400 shares during the last quarter. Finally, Northern Trust Corp grew its position in Cytosorbents by 22.3% during the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after purchasing an additional 16,701 shares during the last quarter. Hedge funds and other institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.